<DOC>
	<DOCNO>NCT00133354</DOCNO>
	<brief_summary>The purpose study see Arimidex , aromatase inhibitor , delay epiphyseal fusion increase predict adult height boy growth hormone deficient , puberty , take growth hormone . This double blind , placebo control 3 year trial .</brief_summary>
	<brief_title>Arimidex Multicenter Trial Growth Hormone ( GH ) Deficient Boys</brief_title>
	<detailed_description />
	<mesh_term>Hypopituitarism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Growth hormone deficient formal test two provocative agent . Treated growth hormone minimum 6 month prior study entry . Growth hormone dose must maintain 0.20.4mg/kg/wk protocol . Stable organic pathology Presence puberty [ genital Tanner Stage &gt; II ( &gt; 4cc testicular volume ) ] Bone age ( BA ) &gt; = 11.5 year &lt; 15 year Participation trial involve hormone therapy least 6 month prior . Chronic illness require long term medication impair growth . ( Stable patient occasional asthma , patient Ritalin Adderall patient topical acne medication may include ) . Hereditary disease diagnose clinically . Moderate severe scoliosis .</criteria>
	<gender>Male</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Puberty</keyword>
	<keyword>Growth hormone deficiency</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>estrogen</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>short stature</keyword>
</DOC>